esomeprazole + flupentixol + melitracen

esomeprazole + Deanxit is a combination therapy investigated for the treatment of gastroesophageal reflux disease (GERD) in patients with comorbid emotional or mood disorders. The combination consists of esomeprazole, a proton pump inhibitor (PPI), and Deanxit, which is itself a fixed-dose combination of flupentixol and melitracen. Esomeprazole works by inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, thereby reducing gastric acid secretion and alleviating the physical symptoms of GERD. Deanxit provides psychotropic effects; flupentixol is a thioxanthene neuroleptic that acts as a dopamine D1 and D2 receptor antagonist at low doses, while melitracen is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin. This multi-component approach aims to address the bidirectional relationship between gastrointestinal symptoms and psychological distress, potentially offering superior symptom relief compared to PPI monotherapy in this specific patient population.

Brand names

Nexium

Other names

esomeprazole + Deanxitesomeprazole + flupentixol/melitracen